Compare Enact Holdings Inc (ACT) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Enact Holdings Inc vs Merck & Co., Inc. — how do they compare? Enact Holdings Inc trades at $45.14 (market cap $6.35B), while Merck & Co., Inc. trades at $126.87 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 50.1× Enact Holdings Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| ACT | MRK | |
|---|---|---|
Market Cap | $6.35B | $318.26B |
Sector | Technology | Health |
52-Week High | $45.71 | $129.52 |
52-Week Low | $34.39 | $77.60 |
Enterprise Value | $6.55B | $361.68B |
Dividend Yield | 1.91% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACT trades at $45.69, up 0.77% today, with a bullish technical signal and strong moving averages. The stock shows robust fundamentals with a net income margin of 54.49% and a P/E ratio of 9.89. Recent news includes a 14% dividend increase announced on May 5, 2026, and Q1 2026 earnings that met expectations. Analyst consensus is a $47.50 price target with a mix of buy and hold ratings.
Outlook remains positive due to high profitability and dividend growth, but risks include earnings volatility and market sensitivity. Upside is supported by institutional sentiment and consistent cash flow, though investors should monitor execution against future earnings estimates.
Merck (MRK) trades at $125.84, down 0.74% on the day, with a bullish technical outlook and strong institutional support. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives amid positive analyst sentiment.
The stock offers upside to the $139.33 consensus price target, supported by solid profitability and cash flow, but faces risks from rising debt levels and competitive pressures in the pharma sector. Investors should weigh the growth potential from M&A against execution risks and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enact Holdings Inc
Enact Holdings is a leading private mortgage insurance provider in the U.S. It partners with lenders to offer credit enhancement and risk management solutions, helping more borrowers achieve and maintain homeownership.
Read more on ACT →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
